William Blair has recently initiated Tenaya Therapeutics Inc (TNYA) stock to Outperform rating, as announced on June 10, 2024, according to Finviz. Earlier, on November 30, 2023, Leerink Partners had initiated the stock to Outperform, setting a price target of $7. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Tenaya Therapeutics Inc (TNYA) Stock Trading Recap
On Friday, Tenaya Therapeutics Inc (TNYA) stock saw a decline, ending the day at $2.04 which represents a decrease of $-0.11 or -5.12% from the prior close of $2.15. The stock opened at $2.21 and touched a low of $1.99 during the day, reaching a high of $2.52. The volume of shares traded was 2.72 million exceeding the average volume of 0.42 million.
Sponsored
TNYA Stock Performance and Moving Averages
In recent trading, Tenaya Therapeutics Inc (TNYA) stock price has shown some volatility, fluctuating 15.25% over the last five trades and -6.85% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -52.78%, and it has plunged by -44.41% in the previous three months. Currently, TNYA is trading at 10.00%, -10.02%, and -45.72% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, TNYA, a Healthcare sector stock, is trading -70.90% below its 52-week high but remains 26.71% above its 52-week low. The Average True Range (ATR) (14 days) of 0.2 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Tenaya Therapeutics Inc’s Profitability and Valuation Ratios
Tenaya Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -52.78%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Tenaya Therapeutics Inc’s market capitalization stands at $160.94 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 1.2, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.22% of Tenaya Therapeutics Inc (TNYA)’s shares, while financial institutions hold 56.59%.
